Absci Expands Drug Discovery Capabilities with Opening of Absci AI Research Lab in New York City

VANCOUVER, Wash. and NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the opening of the Absci AI Research Lab (“AAIR Lab”) in Manhattan’s Plaza District.

This office opening comes on the heels of Absci’s recent breakthrough achievements in machine learning for in silico antibody lead optimization, as well as its announcement of its collaboration with NVIDIA. The AAIR Lab, as a hub of Absci’s AI research, will build on these recent successes and continue to advance the nature and scope of therapeutic protein design.

“Absci’s expansion into one of the geographic hearts of AI research marks an exciting milestone for our team and brings us closer to our vision for de novo drug and cell line design entirely in silico,” said Sean McClain, founder and CEO of Absci. “We’re eager to tap into the deep talent pool in New York, the Northeast, and beyond, as we leverage game-changing technology to deliver better drugs to patients faster, all while collaborating in a beautiful space just steps from Central Park.”

The new AAIR Lab is located on the 43^rd floor of Carnegie Hall Tower; with panoramic views of Central Park, the light-filled office is designed to energize and inspire innovation. The AAIR Lab will support the expansion of Absci’s Denovium™ Engine AI platform and deployment of its machine learning pipeline for predicting therapeutic protein sequences and cell line designs to optimize drug candidates for desired characteristics. The ongoing development of the AI models is enabled by Absci’s synthetic biology platform and the data it generates in its extensive wet lab. The combination of breakthrough AI technologies along with proprietary data production capabilities support Absci’s progress toward design of target-directed protein drug candidates fully in silico.

“The AAIR Lab is a space dedicated to training and bettering Absci’s machine learning models and computational pipeline,” said Absci Lead AI Scientist Joshua Meier. “It’s incredibly rewarding to walk into the office each day knowing that everyone is driven by the shared passion for AI and biologic drug design. I’m thrilled to be building out our New York-based AI group, which will join our existing multinational team of world-class AI experts as we make strides to accelerate drug discovery with the speed and scale of computation.”

About Absci

Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic™ Proteins containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com and follow us on social media: Twitter: @Abscibio, LinkedIn: @absci, and subscribe to our Absci YouTube channel.

Availability of Other Information about Absci

Investors and others should note that we routinely communicate with investors and the public using our website (www.absci.com) and our investor relations website (investors.absci.com), including without limitation, through the posting of investor presentations, SEC filings, press releases, public conference calls and webcasts on these websites. The information that we post on these websites could be deemed to be material information. As a result, investors, the media, and others interested in Absci are encouraged to review this information on a regular basis. The contents of our website, or any other website that may be accessed from our website, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Forward-Looking Statements

Certain statements relating to Absci in this press release that are not historical facts are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements containing the words “will,” “aim,” “may,” "pursues," “anticipates,” “plans,” “believes,” “forecast,” “estimates,” “expects,” “progress,” and “intends,” or similar expressions. We intend these forward-looking statements, including statements regarding technology development and research collaboration efforts, advancements toward in silico drug design and hiring efforts, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and we make this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved, and, furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, risks and uncertainties relating to our ability to attract, hire and retain key personnel; along with those risks set forth in our most recent periodic report filed with the U.S. Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.

Absci Investor Contact

investors@absci.com 

Absci Media Contact

press@absci.com